These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 16728703)

  • 1. The molecular classification of multiple myeloma.
    Zhan F; Huang Y; Colla S; Stewart JP; Hanamura I; Gupta S; Epstein J; Yaccoby S; Sawyer J; Burington B; Anaissie E; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Walker R; Zangari M; Crowley J; Barlogie B; Shaughnessy JD
    Blood; 2006 Sep; 108(6):2020-8. PubMed ID: 16728703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
    Zhan F; Tian E; Bumm K; Smith R; Barlogie B; Shaughnessy J
    Blood; 2003 Feb; 101(3):1128-40. PubMed ID: 12393520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
    Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
    J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
    Broyl A; Hose D; Lokhorst H; de Knegt Y; Peeters J; Jauch A; Bertsch U; Buijs A; Stevens-Kroef M; Beverloo HB; Vellenga E; Zweegman S; Kersten MJ; van der Holt B; el Jarari L; Mulligan G; Goldschmidt H; van Duin M; Sonneveld P
    Blood; 2010 Oct; 116(14):2543-53. PubMed ID: 20574050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early genetic events provide the basis for a clinical classification of multiple myeloma.
    Kuehl WM; Bergsagel PL
    Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
    Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
    Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
    Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
    Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of molecular subtyping multiple myeloma using gene expression profiling.
    Weinhold N; Heuck CJ; Rosenthal A; Thanendrarajan S; Stein CK; Van Rhee F; Zangari M; Hoering A; Tian E; Davies FE; Barlogie B; Morgan GJ
    Leukemia; 2016 Feb; 30(2):423-30. PubMed ID: 26526987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
    Tian E; Sawyer JR; Heuck CJ; Zhang Q; van Rhee F; Barlogie B; Epstein J
    Genes Chromosomes Cancer; 2014 Jul; 53(7):549-57. PubMed ID: 24638926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
    Moreaux J; Klein B; Bataille R; Descamps G; Maïga S; Hose D; Goldschmidt H; Jauch A; Rème T; Jourdan M; Amiot M; Pellat-Deceunynck C
    Haematologica; 2011 Apr; 96(4):574-82. PubMed ID: 21173094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
    Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
    Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
    Zhan F; Hardin J; Kordsmeier B; Bumm K; Zheng M; Tian E; Sanderson R; Yang Y; Wilson C; Zangari M; Anaissie E; Morris C; Muwalla F; van Rhee F; Fassas A; Crowley J; Tricot G; Barlogie B; Shaughnessy J
    Blood; 2002 Mar; 99(5):1745-57. PubMed ID: 11861292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
    Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
    Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Many multiple myelomas: making more of the molecular mayhem.
    Chesi M; Bergsagel PL
    Hematology Am Soc Hematol Educ Program; 2011; 2011():344-53. PubMed ID: 22160056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular compendium of genes expressed in multiple myeloma.
    Claudio JO; Masih-Khan E; Tang H; Gonçalves J; Voralia M; Li ZH; Nadeem V; Cukerman E; Francisco-Pabalan O; Liew CC; Woodgett JR; Stewart AK
    Blood; 2002 Sep; 100(6):2175-86. PubMed ID: 12200383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
    Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
    Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.